PS
OLMA icon

Principal Securities’s Olema Pharmaceuticals OLMA Stock Holding History

Principal Securities’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-466
Closed -$4.56K – 2820
2025
Q3 		$4.56K Buy
+466
New +$2.8K ﹤0.01% 2993

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Principal Securities's OLMA Position: Q4 2025 in Review

Principal Securities sold out of Olema Pharmaceuticals (OLMA) in Q4 2025, closing a stake of 466 shares — an estimated $4.56K sold.

Principal Securities first reported a position in OLMA in Q3 2025 and held it in 1 quarter. The position peaked at $4.56K in Q3 2025. 200 funds tracked by Wall St. Rank hold OLMA as of Q4 2025.

  • Principal Securities reported no remaining Olema Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 466 Olema Pharmaceuticals shares in Q4 2025, an estimated $4.56K.
  • Principal Securities first reported a position in Olema Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Principal Securities's Olema Pharmaceuticals position peaked at $4.56K in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.